Role of Zonisamide in Advanced Parkinson's Disease (PD) in Egyptian Population: Pilot Study
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
Zonisamide (ZNS) (1,2-Benzisoxazole-3-methanesulfonamide) is an anti-epileptic drug. In three
double blinded placebo controlled studies, ZNS- as an adjunctive treatment- showed beneficial
effects on motor symptoms of PD with a low incidence of adverse events. As a result 25 mg
daily of ZNS was approved in 2009 in Japan as an adjunctive treatment in PD patients whose
condition responded insufficiently to Levodopa treatment.
Most observations of a beneficial effect of ZNS have been in Japanese people, and the
antiparkinsonian mechanism of action is unclear. So, ZNS is a promising but still
investigational drug to treat PD and more studies are warranted.
this study will investigate the efficacy and tolerability of Zonisamide as an adjunctive
treatment in Egyptian patients with advanced PD, including motor fluctuations, levodopa
induced dyskinesia and existing nonmotor symptoms. Additionally it investigates its effects
on quality of life of PD patients.